International Congress on
Biological, Physical And Chemical Studies

The International Congress on Biological, Physical And Chemical Studies - is an international conference platform under open open-access- access policy. The conference is led by international expert members who take an objective approach to peer review, ensuring each research paper is reviewed, edited by authors and evaluated on its own scholarly merits and research integration. Publishing and joining the proceeding of the International Congress on Biological, Physical And Chemical Studies will ensure publishing experience and indexing possibilities on various global indexing.

Hepatitis B Virus and Clinical manifestations of enteroviruses Unpacking the Pathophysiological Links and Clinical Ramifications

Hameed Ammar Majeed Hameed
International Sakharov Environmental Institute
of Belarusian State University

Andrey V. Bakunovich
Academic Supervisor:
PhD in Biological sciences

Abstract: Hepatitis B virus (HBV) infection has continued to be a health issue with millions of people suffering from it all over the world. This study hopes to find out the prevalent diseases and the symptoms that accompany HBV infection. In the course of a literature review, some of the clinical features of HBV which have been described include acute hepatitis, chronic hepatitis, hepatitis-associated cirrhosis, and hepatocellular carcinoma. Some of the signs and symptoms seen in persons with HBV include; malaise, icterus, vague abdominal discomfort, and anorexia. This understanding of the various manifestations of this potentially infectious illness is instrumental in its diagnosis and treatment, as well as in its containment. The analysis presented here informs the reader about the illness and its burden, advocates for eliminating this infection, and draws attention to significant measures of public health.

Keywords: Hepatitis B virus (HBV), infection , virus , ORF

Introduction

The Hepatitis B virus was first identified and characterized in 1989, following a series of investigations which revealed the genome of the non-A non-B hepatitis virus (NANB). This led to the recognition that the Hepatitis B virus is the primary cause of this type of hepatitis and an important cause of chronic hepatitis. Cell cultures were unable to be infected, and the only useful experimental animal is the chimpanzee[1]. The most noteworthy aspect of HCV infection is its capacity to persist despite the presence of a robust humoral and cellular immune response from the host. This is attributed to a high mutation rate, which enables the virus to evade immune detection and facilitates its production and clearance. The rate of production and clearance of Hepatitis B viruses (HBV) is estimated to be 10^{12} virions per day, with a virion half-life of 2.7 hours. [2] HBV contains an RNA genome, which is surrounded by an icosahedral capsid (core) and an envelope that contains two glycoproteins, E1 and E2. The diameter of the viral particles is approximately 50 nm, while that of the core is approximately 30 nm. The size and genetic organisation of HCV are similar to those of the Flaviviridae, and as a consequence, the International Committee on Taxonomy of Viruses has proposed that this virus be assigned to the Flaviviridae family. The genome (see Figure 1) is a single-stranded positive-sense RNA molecule of approximately 10,000 bases in length, with

a single open reading frame (ORF) that expresses a protein of approximately 3,011 amino acids. [3]

Method

Hepatitis is defined as an inflammatory process affecting the liver. The liver is a vital organ with a number of functions, including the processing of nutrients, the filtration of blood, and the fight against infection. In the event of liver inflammation or damage, the functionality of this vital organ may be compromised. [4] The excessive consumption of alcohol, the presence of toxins, the use of certain medications, and the existence of specific medical conditions can all result in the development of hepatitis. In the majority of cases, hepatitis is caused by a virus. In the United States, the most prevalent forms of viral hepatitis are hepatitis A, hepatitis B, and Hepatitis B. While the clinical manifestations of these conditions are similar, they are transmitted through distinct routes, respond to disparate therapeutic modalities, and exhibit varying degrees of severity[5].

It is not uncommon for individuals infected with Hepatitis B to be asymptomatic and unaware of their infection. In the event of symptoms manifesting, they may include jaundice, anorexia, gastric distress, emesis, abdominal discomfort, pyrexia, discolored urine, pale stools, arthralgia and fatigue. In the event of a new infection, symptoms typically manifest within a period of 2 to 12 weeks; however, in some cases, this may extend up to 6 months. It is noteworthy that individuals with chronic Hepatitis B may endure years without exhibiting any symptoms or experiencing illness. Conversely, when symptoms do arise in those with chronic Hepatitis B, they frequently indicate an advanced stage of liver disease[6].

Diagnosis is made with liver function tests and serologic testing to identify the virus. Proper hygiene and universal precautions can prevent acute viral hepatitis. Depending on the causative virus, pre-exposure and post-exposure prophylaxis with vaccines or serum globulins may be administered.

Clinical manifestations of viral hepatitis

Regardless of the mode of transmission, all types of viral hepatitis affect liver cells. This explains why many signs and symptoms of different types of infection are similar. On the other hand, since the liver is involved in different metabolic functions, patients with viral hepatitis tend to have general symptoms. [7]As the disease progresses, the liver becomes more sensitive due to the enlargement of the existing liver and other symptoms occur. However, the main feature of the clinical manifestations of viral hepatitis refers to the variability of symptoms. The symptoms of viral hepatitis vary greatly from one individual to another, even when the causative agent is the same, and it is therefore impossible to distinguish between different hepatitis viruses based on clinical manifestations. [8]

Clinical manifestations of enteroviruses

Infections with enteroviruses (HAV and HEV) can cause a wide range of clinical manifestations, ranging from subclinical infection, especially in children, to fulminant hepatitis, although they generally cause only acute, self-limiting disease.

Hepatitis B acute infection phases have an incubation period of about 45 -120 days and depend on the inoculating dose, the mode of transmission, and social factors and health conditions of the host and the virus[9]. Therapeutic measures. The pre-bilious stage can last several days to a week, during which no jaundice appears, and is characterized by low-grade fever, weariness, lethargy, myalgia, and emesis. In contrast to hepatitis A, the disease onset is gradual, accompanied by weight loss and slight right-sided abdominal discomfort that is caused by the enlarged liver which develops several weeks ahead of jaundice in the status. The icteric phase normally sets in around ten days from the first symptoms and is typically an afebrile stage. The liver is enlarged to about 20 cm where it is palpable. Its reduction in size would mean that there is undergoing massive cell death. Fulminant hepatitis occurs in 4% of the instances, with these patients having a death risk of between 70 and 90%, however, it is worth noting that levels of survival are lesser than hepatitis A and are also dependent on age. [10,11]

Conclusion

For long periods, chronic illness can be present in the form of biochemical and histological data without indicating any clinical disease and even patients with this chronic illness do not show clinical or biochemical evidence; they are referred to as asymptomatic carriers or carriers of HBsAg. Generally, cirrhosis develops in less than 10% of mild hepatitis cases.

In cases of hepatitis, regardless of severity, symptoms may be vague. However, common symptoms include fatigue, anxiety, and loss of appetite. In general, at the initial diagnosis, there is no jaundice, ascites or oedema. In 20% of patients, these symptoms are not present. Furthermore, 5% of patients experience intracranial encephalopathy and variceal haemorrhage. Additionally, transaminases, bilirubin and gamma globulin are elevated. It is also common for periods of remission and recurrence to occur.

References

1.Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W, Chen KP. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis. 1982 Aug;146(2):198-204. [PubMed]

2.Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, Mares A, Miller JK, Moyer LA. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 1990 Mar 02;263(9):1218-22. [PubMed]

3.Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-1599. [PMC free article] [PubMed]

4.Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012 Aug;56(2):422-33. [PubMed]

5.Higgins DC, Kuncio DE, Johnson CC, Viner KM. Influence of birth origin and risk factor profile on hepatitis B mortality: Philadelphia, PA 2003-2013. Ann Epidemiol. 2018 Mar;28(3):169-174. [PubMed]

6.Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and future challenges. QJM. 2012 Feb;105(2):109-13. [PMC free article] [PubMed]

7.Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis. 2012 May;16(2):347-69. [PubMed]

8.Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris). 2010 Aug;58(4):258-66. [PMC free article] [PubMed]

9.Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology. 2009 May;49(5 Suppl):S61-71. [PubMed]

10.Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014 Dec 06;384(9959):2053-63. [PubMed]

11.Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther. 2011;16(8):1169-86. [PubMed]